Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Zeffix 100 mg Film-coated tablet
Medicines register · Ireland

Zeffix 100 mg Film-coated tablet

Authorisation EU/1/99/114/002 · GlaxoSmithKline Trading Services Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
GlaxoSmithKline Trading Services Limited (all products →)
Active substance
Lamivudine
Clinical trials
7 clinical trials →
Dosage form
Film-coated tablet
Route of administration
Oral use
ATC codes
J05AF, J05AF05
First authorised
29/07/1999
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Lamivudine: supply and approvals

20 authorised products on the HPRA list contain Lamivudine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
Lamivudine Injection: resolved, updated 16 Nov 2026
Lamivudine Tablet: resolved, updated 19 Oct 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 114. It has been authorised for 27 years (since 29 July 1999). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Lamivudine in Ireland

19 other products on the HPRA list contain Lamivudine, from 6 licence holders; 1 of them is marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Abacavir/Lamivudine Viatris 600 mg/300 mg Film-coated TabletsViatris LimitedNational authorisation (PA)Marketed
Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tabletsMcDermott Laboratories Ltd., T/A Gerard LaboratoriesNational authorisation (PA)Not marketed
Combivir 150 mg/300 mg film-coated tabletsViiV Healthcare BVCentralised EU authorisationNot stated
Combivir 150 mg/300 mg film-coated tabletsViiV Healthcare BVCentralised EU authorisationNot stated
Delstrigo 100 mg/300 mg/245 mg film-coated tabletsMerck Sharp & Dohme BV,Centralised EU authorisationNot stated
Dovato 50 mg/300 mg tabletsViiV Healthcare BVCentralised EU authorisationNot stated
Epivir 10 mg/ml oral solutionViiV Healthcare BVCentralised EU authorisationNot stated
Epivir 150 mg film-coated tabletsViiV Healthcare BVCentralised EU authorisationNot stated
Epivir 300 mg film-coated tabletsViiV Healthcare BVCentralised EU authorisationNot stated
KIVEXAViiV Healthcare BVCentralised EU authorisationNot stated
Lamivudine Teva 100 mg film-coated tabletsTeva Pharma B.V.Centralised EU authorisationNot stated
Lamivudine Teva Pharma B.V. 150 mg film-coated tabletsTeva Pharma B.V.Centralised EU authorisationNot stated

All 20 products with Lamivudine →

Other substances in ATC group J05AF

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group J05AF with this product:

Entecavir (5) · Tenofovir disoproxil fumarate (5) · Zidovudine (3) · Emtricitabine (1) · ENTECAVIR MONOHYDRATE (1) · Tenofovir disoproxil (1) · Tenofovir disoproxil phosphate (1) · Tenofovir alafenamide (1) · Abacavir sulfate (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

GlaxoSmithKline Trading Services Limited holds 28 products on the HPRA list, with 14 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.